Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US

J. R. Ingram, V. Bettoli, J. I. Espy, G. Kokolakis, A. Martorell, A. P. Villani, H. Wallinger, E. Coak, T. Kasparek, E. Muscianisi, C. Richardson, A. B. Kimball

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory, debilitating skin disease characterized by painful deep lesions and associated with substantial disease burden. Objectives: The objective of this study was to describe physician- and patient-reported clinical unmet needs from a real-world perspective. Methods: This study used data from the Adelphi HS Disease Specific Programme, a point-in-time survey of dermatologists and their patients with HS in Europe and the United States. Dermatologists completed patient record forms (PRFs) for 5–7 consecutively consulting patients with HS; patients or carers of patients also optionally completed a patient/carer self-completion questionnaire (PSC/CSC). Data collection included demographics, symptomatology and impact on quality of life (QoL). Results: Dermatologists (N = 312) completed PRFs for 1787 patients with HS; patient- and carer-reported questionnaires (PSC/CSC) were completed for 33.1% (591/1787) of patients. The mean age was 34.4 ± 12.2 years and 57.6% of patients were female (1029/1787). Physician-judged disease severity at sampling was categorized as mild in 66.0% (1179/1787), moderate in 29.3% (523/1787) and severe in 4.7% (85/1787) of patients. Deterioration or unstable condition over the previous 12 months was described by 17.1% [235/1372] and 12.6% [41/325] of physician- and patient/carer-reported cases, respectively. Despite receiving treatment, high proportions of patients still experienced symptoms at sampling (general pain/discomfort [49.5%, 885/1787]; inflammation/redness of lesions/abscesses [46.1%, 823/1787] and itching [29.9%, 535/1787]); these symptoms were more frequent in patients with moderate or severe disease. Patients reported a mean Dermatology Life Quality Index score of 5.9 ± 5.4 (555/591; mild, 4.1 ± 4.3; moderate, 9.4 ± 5.4; severe, 13.3 ± 5.5) and a mean Hidradenitis Suppurativa Quality of Life score of 11.0 ± 10.6 (518/591; mild, 7.6 ± 8.3; moderate, 17.7 ± 10.0; severe, 31.0 ± 15.4) indicating a substantial impact on QoL. Conclusions: Patients with HS experienced a high disease burden despite being actively treated by a dermatologist. This study demonstrates that the burden of HS disease is generally poorly managed with a considerable impact observed on patients' QoL.

Original languageEnglish
Pages (from-to)1597-1605
Number of pages9
JournalJournal of the European Academy of Dermatology and Venereology
Volume36
Issue number9
DOIs
StatePublished - Sep 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US'. Together they form a unique fingerprint.

Cite this